July 13, 2024

error page

Business is my step

MorphoSys Appoints Sung Lee as Main Monetary Officer

5 min read
MorphoSys Appoints Sung Lee as Main Monetary Officer
MorphoSys Appoints Sung Lee as Main Monetary Officer

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 6, 2021 / MorphoSys AG (FSE:MOR Prime Common Segment MDAX & TecDAX NASDAQ:MOR), a industrial-phase biopharmaceutical organization and a leader in antibody, protein and peptide systems, introduced right now the appointment of Sung Lee as Main Economical Officer, effective February 2, 2021. Mr. Lee succeeds Jens Holstein, who stepped down in December 2020, and will direct all company finance capabilities as a member of the Administration Board of MorphoSys AG. He will be based in Planegg, Germany.

Sung Lee

“I am delighted to welcome Sung to MorphoSys when the organization executes on its to start with commercial launch and is establishing alone as an emerging leader in hematology-oncology and autoimmune conditions,” said Marc Cluzel, M.D., Ph.D., Chairman of the MorphoSys Supervisory Board. “Sung will bring a wealth of experience to the Management Board primarily based on his excellent observe record in scaling companies and foremost finance and investor relations capabilities in the U.S. and Europe.”

Jean-Paul Kress, M.D., Main Govt Officer of MorphoSys, extra: “All over his career, Sung has demonstrated incredible talent in driving economical functionality and serving as a strategic thought partner. We are certain that Sung’s transformative way of thinking will be instrumental in executing our formidable progress strategy and the accelerated progress of our pipeline for the benefit of people.”

“I am thrilled to sign up for MorphoSys and turn out to be element of a crew that has verified its capability to make a true variance for individuals suffering from cancer,” mentioned Sung Lee. “MorphoSys is a prime example of an R&D-focused firm that has effectively advanced into a business-phase enterprise, and I am quite enthusiastic to aid shape its upcoming expansion.”

Sung Lee has a lot more than 20 years of finance leadership working experience in biopharmaceutical and technologies businesses. Mr. Lee joins MorphoSys from Sangamo Therapeutics, Inc., where he served as Chief Money Officer. Prior to that job, Mr. Lee used virtually 14 a long time at Gilead Sciences where by he most lately led the world wide Economical Setting up & Investigation and Investor Relations functions.

Mr. Lee commenced his occupation in the tax advisory company at PriceWaterhouseCoopers LLP. He acquired a Master of Organization Taxation from the University of Southern California and a B.A. in Economics from the College of California, Irvine.

About MorphoSys

MorphoSys is a professional-phase biopharmaceutical enterprise committed to the discovery, growth and commercialization of modern therapies for clients struggling from most cancers and autoimmune ailments. Based mostly on its primary experience in antibody, protein and peptide technologies, MorphoSys, jointly with its companions, has created and contributed to the advancement of a lot more than 100 merchandise candidates, of which 27 are currently in clinical enhancement. In 2017, Tremfya®, produced by Janssen Investigate & Enhancement, LLC and marketed by Janssen Biotech, Inc., for the treatment of plaque psoriasis, turned the initial drug centered on MorphoSys’ antibody technological innovation to acquire regulatory acceptance. In July 2020, the U.S. Foods and Drug Administration (Food and drug administration) granted accelerated acceptance of the company’s proprietary merchandise Monjuvi® (tafasitamab-cxix) in mix with lenalidomide in patients with a specific type of lymphoma.

Headquartered in close proximity to Munich, Germany, the MorphoSys group, together with the absolutely owned U.S. subsidiary MorphoSys US Inc., has much more than 600 workforce. More info at www.morphosys.com or www.morphosys-us.com.

Monjuvi® and HuCAL® are registered emblems of MorphoSys AG.

Tremfya® is a registered trademark of Janssen Biotech, Inc.

MorphoSys Forward-Hunting Statements

This communication includes certain forward-hunting statements about the MorphoSys team of providers, including the expectations relating to Monjuvi’s skill to take care of sufferers with relapsed or refractory diffuse big B-cell lymphoma, the even more medical improvement of tafasitamab-cxix, together with ongoing confirmatory trials, additional interactions with regulatory authorities and anticipations concerning foreseeable future regulatory filings and doable additional approvals for tafasitamab-cxix as properly as the commercial general performance of Monjuvi. The text “anticipate,” “believe,” “estimate,” “anticipate,” “intend,” “could,” “system,” “forecast,” “undertaking,” “would,” “could,” “probable,” “doable,” “hope” and similar expressions are intended to recognize ahead-wanting statements, though not all forward-searching statements contain these figuring out phrases. The forward-hunting statements contained herein symbolize the judgment of MorphoSys as of the day of this launch and contain known and mysterious threats and uncertainties, which could bring about the real success, fiscal situation and liquidity, performance or achievements of MorphoSys, or sector outcomes, to be materially unique from any historic or long run effects, economical conditions and liquidity, efficiency or achievements expressed or implied by this sort of ahead-wanting statements. In addition, even if MorphoSys’ outcomes, performance, money problem and liquidity, and the growth of the field in which it operates are constant with these kinds of forward-hunting statements, they could not be predictive of success or developments in future periods. Amid the things that may perhaps final result in discrepancies are MorphoSys’ anticipations with regards to threats and uncertainties connected to the affect of the COVID-19 pandemic to MorphoSys’ business enterprise, functions, system, objectives and expected milestones, together with its ongoing and prepared research actions, means to perform ongoing and planned scientific trials, clinical provide of present or upcoming drug candidates, industrial source of present or long term authorized goods, and launching, marketing and advertising and selling present-day or potential authorized products, the world collaboration and license settlement for tafasitamab, the even further clinical progress of tafasitamab, such as ongoing confirmatory trials, and MorphoSys’ capability to get hold of and sustain requisite regulatory approvals and to enroll people in its prepared medical trials, extra interactions with regulatory authorities and anticipations regarding foreseeable future regulatory filings and possible extra approvals for tafasitamab-cxix as nicely as the commercial functionality of Monjuvi, MorphoSys’ reliance on collaborations with third get-togethers, estimating the professional opportunity of its development plans and other risks indicated in the chance things integrated in MorphoSys’ Annual Report on Sort 20-F and other filings with the U.S. Securities and Trade Commission. Given these uncertainties, the reader is recommended not to put any undue reliance on this kind of ahead-searching statements. These ahead-on the lookout statements converse only as of the date of publication of this doc. MorphoSys expressly disclaims any obligation to update any such forward-on the lookout statements in this doc to replicate any improve in its expectations with regard thereto or any adjust in functions, problems or conditions on which any these kinds of statement is based or that may affect the likelihood that true effects will vary from people set forth in the ahead-hunting statements, unless of course particularly required by law or regulation.

For a lot more info, please make contact with:

Media Contacts:Thomas BiegiVice PresidentTel.: +49 ()89 / 89927 26079[email protected] Trader Contacts:Dr. Julia NeugebauerSenior DirectorTel: +49 ()89 / 899 27 179[email protected]
Jeanette BressiDirector, US CommunicationsTel: +1 617-404-7816[email protected] Myles CloustonSenior DirectorTel: +1 857-772-0240[email protected]

Supply: MorphoSys AG

Watch resource model on accesswire.com:

error-page.com © All rights reserved. | Newsphere by AF themes.